With prospects for an AstraZeneca Plc deal falling apart, Pfizer Inc. Chief Executive Officer Ian Read is facing a new question from investors: What now?
Jeff Jonas, an analyst at Gabelli & Co., says he recommends shares of Bristol-Myers Squibb and Watson Pharmaceuticals. Jonas talks with Bloomberg's Ken Prewitt, Tom Keene and Sara Eisen on Bloomberg Radio's "Bloomberg Surveillance."
Covidien Plc., a maker of surgical products and drugs, plans to spin off its pharmaceuticals division into a separate company that would be better able to compete in the growing pain-management area.
Mylan Inc., the biggest U.S. generic-drug maker, was rejected in its bid to buy Meda AB, the Swedish pharmaceuticals maker valued at about $4.5 billion.
"The tensions have been growing between the two companies, with Walgreen having to push out their own CFO and president of pharmacy."
- Jeff Jonas on Dec 10, 2014
The Bloomberg Advantage: Jonas on Healthcare, Dwyer on Book
Jonas Discusses Cigna Pharmacy-Benefits Division
Bloomberg Surveillance: Levkovich, Moffatt and Jonas
Gabelli's Jonas Discusses Allegran, Valeant Deal (Audio)
Gabelli’s Jonas Says CVS Can Maintain Current Growth (Audio)